Investigation on Safety of Influenza A H1N1 Split Virus Influenza Vaccine Vaccination During the Epidemic of Pandemic Influenza A in Shanghai,2009

袁政安,张涛,顾宝柯,陈昕,陈健,王丹,李善国,赵根明

DOI: https://doi.org/10.19914/j.cjvi.2010.04.008

2010-01-01

Abstract:Objective To investigate the Influen AH1N1 split virus influenza vaccine safety of mass vaccination during pandemic influenza The Influen AH1N1 influenza vaccine in Shanghai in 2009, Methods A survey on the vaccination of influenza AH1N1 influenza vaccine was conducted in Shanghai from Oct to Dec 2009. At the same time, the information of incidence, characteristics and outcome of adverse reactions were collected. Results From Oct 15 to Dec 31, 2009, 1 373 496 doses Influenza AH1N1 influenza vaccine were administered in Shanghai. The total reported adverse events following immunization (AEFI) were 620 cases, reported incidence was 45.14 per 100 000, 95%. Confidence Interval (CI) was 42 per 100 000 ～ 49 per 100 000. Mild adverse reaction were 531 cases, account for 85 % , reported incidence was 38.66 per 100 000. The major syndrome of mild adverse reaction was fever. The reported moderate adverse reaction were 37 cases, reported incidence was 2.69 per 100 000. The major syndrome of moderate adverse reaction was allergy. Most of the adverse reaction disappeared or cured within 48 hours. There was no severe adverse reaction had been reported. Conclusion The influenza AH1N1 vaccine was safe. The reported incidence of AEFI was low, the most cases were mild adverse reaction, and no reported severe adverse reaction.